• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实用的实体瘤PET反应标准简化指南1.0(PERCIST):实体瘤PET反应标准简化指南1.0

Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.

作者信息

O Joo Hyun, Lodge Martin A, Wahl Richard L

机构信息

From the Division of Nuclear Medicine, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Md.

出版信息

Radiology. 2016 Aug;280(2):576-84. doi: 10.1148/radiol.2016142043. Epub 2016 Feb 24.

DOI:10.1148/radiol.2016142043
PMID:26909647
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4976461/
Abstract

Positron Emission Tomography (PET) Response Criteria in Solid Tumors (PERCIST 1.0) describes in detail methods for controlling the quality of fluorine 18 fluorodeoxyglucose PET imaging conditions to ensure the comparability of PET images from different time points to allow quantitative expression of the changes in PET measurements and assessment of overall treatment response in PET studies. The steps for actual application of PERCIST are summarized. Several issues from PERCIST 1.0 that appear to require clarification, such as measurement of size and definition of unequivocal progression, also are addressed. (©) RSNA, 2016.

摘要

实体瘤正电子发射断层显像(PET)反应标准(PERCIST 1.0)详细描述了控制氟-18氟脱氧葡萄糖PET成像条件质量的方法,以确保不同时间点PET图像的可比性,从而能够定量表达PET测量值的变化,并在PET研究中评估整体治疗反应。总结了PERCIST实际应用的步骤。还讨论了PERCIST 1.0中一些似乎需要澄清的问题,如大小测量和明确进展的定义。(©)RSNA,2016年。

相似文献

1
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.实用的实体瘤PET反应标准简化指南1.0(PERCIST):实体瘤PET反应标准简化指南1.0
Radiology. 2016 Aug;280(2):576-84. doi: 10.1148/radiol.2016142043. Epub 2016 Feb 24.
2
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.使用氟代脱氧葡萄糖正电子发射断层扫描评估肿瘤反应:实体瘤疗效评价标准的更新、与欧洲癌症研究与治疗组织标准的比较以及未来发展线索
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):55-66. doi: 10.1007/s00259-017-3687-3. Epub 2017 Mar 30.
3
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.从RECIST到PERCIST:实体瘤中PET反应标准的不断演变的考量
J Nucl Med. 2009 May;50 Suppl 1(Suppl 1):122S-50S. doi: 10.2967/jnumed.108.057307.
4
Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.实体瘤中RECIST和PERCIST标准的比较:一项汇总分析与综述
Oncotarget. 2016 May 10;7(19):27848-54. doi: 10.18632/oncotarget.8425.
5
Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold.实体瘤正电子发射断层扫描反应标准:用于[18F] - 氟脱氧葡萄糖正电子发射断层扫描与计算机断层扫描相结合以评估转移性实体瘤治疗反应的定量分析标准:闪光的未必都是金子。
Eur J Cancer. 2016 Mar;56:54-58. doi: 10.1016/j.ejca.2015.12.017. Epub 2016 Jan 22.
6
Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.EORTC 标准与 PERCIST 标准在评估接受伊立替康和西妥昔单抗治疗的转移性结直肠癌患者 PET/CT 疗效中的比较。
J Nucl Med. 2013 Jul;54(7):1026-31. doi: 10.2967/jnumed.112.111757. Epub 2013 Apr 9.
7
Pitfalls of a Mixed Metabolic Response at PET/CT.PET/CT 中混合代谢反应的陷阱。
Radiographics. 2019 Sep-Oct;39(5):1461-1475. doi: 10.1148/rg.2019180093. Epub 2019 Aug 9.
8
Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).使用实体瘤正电子发射断层扫描(PET)反应标准(PERCIST)1.0来评估2'-脱氧-2'-[18F]氟-D-葡萄糖-PET/CT扫描,以预测局部晚期非小细胞肺癌(NSCLC)治疗早期的生存率。
J Med Imaging Radiat Oncol. 2016 Apr;60(2):231-8. doi: 10.1111/1754-9485.12427. Epub 2015 Dec 18.
9
Assessment of treatment response using PET.使用正电子发射断层显像(PET)评估治疗反应。
PET Clin. 2015 Jan;10(1):9-26. doi: 10.1016/j.cpet.2014.09.002. Epub 2014 Oct 14.
10
Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease.用于恶性疾病分期及再分期的FDG-PET/CT成像中的标准化与定量分析
PET Clin. 2014 Apr;9(2):117-27. doi: 10.1016/j.cpet.2013.10.003. Epub 2013 Dec 5.

引用本文的文献

1
Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [F]FDG PET/CT study.人工智能辅助评估替本他富对转移性葡萄膜黑色素瘤的代谢反应:一项长轴视野[F]FDG PET/CT研究
Eur J Nucl Med Mol Imaging. 2025 Sep 6. doi: 10.1007/s00259-025-07504-8.
2
Accuracy of PET-CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment.PET-CT评估新辅助治疗后临床III期黑色素瘤患者淋巴结病变范围的准确性。
Ann Surg Oncol. 2025 Aug 26. doi: 10.1245/s10434-025-18191-y.
3
[F]FDG PET/CT for treatment monitoring and prediction of progression in retroperitoneal fibrosis.[F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描用于监测腹膜后纤维化的治疗及预测病情进展
Eur J Nucl Med Mol Imaging. 2025 Aug 14. doi: 10.1007/s00259-025-07479-6.
4
Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP.肺癌正电子发射断层显像(PET)及放射性配体疗法的最新进展:氟代脱氧葡萄糖(FDG)与成纤维细胞活化蛋白(FAP)
Cancers (Basel). 2025 Aug 1;17(15):2549. doi: 10.3390/cancers17152549.
5
SBRT in the Very Elderly: A Viable Option for Pulmonary Oligometastases?老年患者的立体定向体部放疗:肺寡转移瘤的可行选择?
Cancers (Basel). 2025 Jul 30;17(15):2512. doi: 10.3390/cancers17152512.
6
Development of lesion and organ negative cast modelling technique for quality assurance and optimization of nuclear medicine images.用于核医学图像质量保证和优化的病变及器官阴性模体建模技术的开发。
Commun Med (Lond). 2025 Jul 22;5(1):303. doi: 10.1038/s43856-025-01009-z.
7
Safety and efficacy of thermal ablation for small cell lung cancer liver metastases.热消融治疗小细胞肺癌肝转移的安全性和有效性。
Transl Lung Cancer Res. 2025 Jun 30;14(6):2309-2316. doi: 10.21037/tlcr-2025-112. Epub 2025 Jun 19.
8
Variability of Metabolic Rate and Distribution Volume Quantification in Whole-Body Parametric PATLAK [F]-FDG PET/CT-A Prospective Trial in Patients with Lung Cancer.全身参数化PATLAK [F]-FDG PET/CT中代谢率和分布容积定量的变异性:一项针对肺癌患者的前瞻性试验
Diagnostics (Basel). 2025 Jul 5;15(13):1719. doi: 10.3390/diagnostics15131719.
9
Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy.利用斑马鱼建立高危儿科癌症模型以指导精准治疗。
Cancer Res Commun. 2025 Jul 1;5(7):1215-1227. doi: 10.1158/2767-9764.CRC-25-0080.
10
New Approaches in Radiotherapy.放射治疗的新方法
Cancers (Basel). 2025 Jun 13;17(12):1980. doi: 10.3390/cancers17121980.

本文引用的文献

1
Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.肿瘤临床试验中18F-FDG PET/CT成像的UPICT方案总结。
J Nucl Med. 2015 Jun;56(6):955-61. doi: 10.2967/jnumed.115.158402. Epub 2015 Apr 16.
2
Optimum lean body formulation for correction of standardized uptake value in PET imaging.用于校正PET成像中标准化摄取值的最佳瘦体重配方。
J Nucl Med. 2014 Sep;55(9):1481-4. doi: 10.2967/jnumed.113.136986. Epub 2014 Jun 24.
3
Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.EORTC 标准与 PERCIST 标准在评估接受伊立替康和西妥昔单抗治疗的转移性结直肠癌患者 PET/CT 疗效中的比较。
J Nucl Med. 2013 Jul;54(7):1026-31. doi: 10.2967/jnumed.112.111757. Epub 2013 Apr 9.
4
Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.用 FDG-PET/CT 评估小细胞肺癌的治疗反应:PERCIST 和 EORTC 标准的预后和比较研究。
Cancer Imaging. 2013 Mar 5;13(1):73-80. doi: 10.1102/1470-7330.2013.0008.
5
Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.初始分期18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描得出的定量参数对高级别非霍奇金淋巴瘤患者的预后价值。
Nucl Med Commun. 2012 Sep;33(9):974-81. doi: 10.1097/MNM.0b013e32835673ec.
6
Noise considerations for PET quantification using maximum and peak standardized uptake value.使用最大标准化摄取值和峰值标准化摄取值进行 PET 定量的噪声考虑因素。
J Nucl Med. 2012 Jul;53(7):1041-7. doi: 10.2967/jnumed.111.101733. Epub 2012 May 24.
7
Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.食管癌新辅助化疗反应评估:实体瘤 PET 反应标准与实体瘤疗效评价标准。
J Nucl Med. 2012 Jun;53(6):872-80. doi: 10.2967/jnumed.111.098699. Epub 2012 May 11.
8
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.从RECIST到PERCIST:实体瘤中PET反应标准的不断演变的考量
J Nucl Med. 2009 May;50 Suppl 1(Suppl 1):122S-50S. doi: 10.2967/jnumed.108.057307.
9
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准:修订的RECIST指南(第1.1版)
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
10
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.荷兰在多中心试验中进行氟代脱氧葡萄糖(FDG)全身PET研究的标准化和定量协议。
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2320-33. doi: 10.1007/s00259-008-0874-2. Epub 2008 Aug 15.